The synthetic peptide AWRK6, derived from frog antimicrobial peptide and acting as a GLP-1 receptor agonist, reversed fatty liver disease in mice by improving lipid and glucose metabolism through the PI3K/AKT/AMPK pathway.
Frog peptide → GLP-1 agonistA synthetic peptide originally designed from a frog antimicrobial compound unexpectedly acts as a GLP-1 receptor agonist, reversing fatty liver in mice
What the researchers found
AWRK6 (novel GLP-1R agonist from frog AMP) alleviated obesity and hepatic steatosis in HED-induced MAFLD mice, improved lipid and glucose metabolism, and activated PI3K/AKT/AMPK/ACC signaling. Confirmed in human HepG2 fatty liver cell model.
Why it matters
MAFLD affects 25%+ of adults globally and has no approved drug. A peptide derived from a natural frog antimicrobial compound that acts through the GLP-1 pathway could represent a novel therapeutic approach, especially given that semaglutide is now being investigated for fatty liver.
The numbers in context
Frog-derived AWRK6; GLP-1R agonist; reduced obesity/steatosis; PI3K/AKT/AMPK/ACC activated; confirmed in HepG2
How the study worked
In vitro and in vivo study. High energy diet-induced MAFLD mice treated with AWRK6 (IP injection). Biochemistry, liver histology, and signaling pathway analysis. Oleic acid-induced HepG2 fatty liver model and insulin sensitivity assays in human cells.
Who was studied
HED-fed obese mice with MAFLD + HepG2 human liver cells
What this study cannot tell us
Mouse model with IP injection — not a practical clinical route. AWRK6 pharmacokinetics and oral bioavailability not assessed. Comparison to existing GLP-1 drugs not performed. Long-term safety unknown.
How to read the evidence
Low-to-moderate evidence: combined in vitro (human cells) and in vivo (mouse) data with pathway elucidation. No clinical data.
When this study was published
Published 2021. GLP-1 drugs for fatty liver disease are now in clinical trials, with semaglutide showing promise.
The bigger picture
The discovery that a frog antimicrobial peptide can be repurposed as a GLP-1 receptor agonist for metabolic disease connects venom/AMP research to the booming GLP-1 drug market. Novel GLP-1 agonist peptides from unexpected natural sources could provide alternatives with unique properties.
Questions still open
- How does AWRK6 compare to semaglutide for fatty liver treatment?
- Can AWRK6 be formulated for subcutaneous or oral delivery?
- Does AWRK6 have additional antimicrobial benefits beyond its GLP-1 activity?
Common questions
Can GLP-1 drugs help with fatty liver?
How was a frog peptide turned into a liver drug?
Read the original research
A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis.
Peptides, 143, 170597
Citation
Jin, Lili; Sun, Yuxin; Li, Yuying; Zhang, Hanyu; Yu, Wenxue; Li, Yiling; Xin, Yi; Alsareii, Saeed Ali; Wang, Qiuyu; Zhang, Dianbao. (2021). A synthetic peptide AWRK6 ameliorates metabolic associated fatty liver disease: involvement of lipid and glucose homeostasis.. Peptides, 143, 170597. https://doi.org/10.1016/j.peptides.2021.170597